Company Description
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide.
The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers.
The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream.
The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
| Country | United States |
| Founded | 1994 |
| IPO Date | Jan 27, 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 237 |
| CEO | Dr. Mark Strobeck Ph.D. |
Contact Details
Address: 30142 Wixom Road Wixom, Michigan 48393 United States | |
| Phone | (800) 449-3353 |
| Website | rockwellmed.com |
Stock Details
| Ticker Symbol | RMTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001041024 |
| CUSIP Number | 774374300 |
| ISIN Number | US7743743004 |
| Employer ID | 38-3317208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Strobeck Ph.D. | President, Chief Executive Officer and Director |
| Megan C. Timmins | Executive Vice President, Chief Legal Officer and Secretary |
| Jesse Neri | Senior Vice President of Finance |
| James A. McCarthy | Senior Vice President of Business and Corporate Development |
| Timothy T. Chole | Senior Vice President of Sales and Marketing |
| Heather R. Hunter | Senior Vice President and Chief Corporate Affairs Officer |
| David J. Kull | Secretary |
| Jason Finkelstein | Investor Relations Representative |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | SCHEDULE 13G/A | Filing |
| Jun 25, 2024 | SCHEDULE 13G/A | Filing |
| Jun 13, 2024 | SCHEDULE 13G/A | Filing |
| May 30, 2024 | SCHEDULE 13G/A | Filing |
| May 30, 2024 | SCHEDULE 13G/A | Filing |
| May 23, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| May 3, 2024 | SCHEDULE 13G | Filing |